Analgesic Effect of Intrathecal Morphine Combined With Low Dose Local Anesthetics on Postoperative Analgesia After Liver Resection

Sponsor
Yonsei University (Other)
Overall Status
Completed
CT.gov ID
NCT05208801
Collaborator
(none)
90
1
3
17
5.3

Study Details

Study Description

Brief Summary

Efficient postoperative pain control plays a vital part in the management of patients after surgery. In particular, major surgeries including hepatectomy cause intense postoperative pain that may result in cardiovascular or respiratory complications post-surgery. One of the current methods of postoperative pain control after hepatectomy involves a multimodal approach including intrathecal morphine injection immediately prior to surgery. Because morphine alone is inadequate for immediate postoperative pain control due to a late peak effect time of 6 hours, current literature advocates a combination injection including bupivacaine. However, higher doses of bupivacaine may inadvertently cause motor block or hemodynamic side effects. The aim of this study was to compare the effectiveness and side effects of intrathecal morphine combined with low dose bupivacaine against intrathecal morphine alone and no intrathecal injection.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

All patients enrolled in the current study will receive intrathecal injections immediately prior to general anesthesia. The patient will be on his or her side in the fetal position and after palpating the back to secure the space between the 3rd and 4th lumbar spine, the area will be properly disinfected and draped with a sterile towel. Using a 25G needle, a small volume of 1% lidocaine will be injected at the proposed puncture site. For the control group, 2ml of 1% lidocaine will be injected subcutaneously with the 25G needle used during local anesthetic injection. For the morphine group and the morphine + bupivacaine group, a 25G pencil point spinal needle will be used to advance into the intrathecal space. After confirming intrathecal position of the needle by CSF regurgitation, morphine 400mg or morphine 400mcg+ bupivacaine 5mg each to a total volume of 2ml will be injected. Afterwards, all patients will undergo general anesthesia by the same method.

Study Design

Study Type:
Interventional
Actual Enrollment :
90 participants
Allocation:
Non-Randomized
Intervention Model:
Factorial Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Analgesic Effect of Intrathecal Morphine Combined With Low Dose Local Anesthetics on Postoperative Analgesia After Liver Resection: A Randomized, Controlled Preliminary Study
Actual Study Start Date :
Nov 19, 2018
Actual Primary Completion Date :
Apr 18, 2020
Actual Study Completion Date :
Apr 18, 2020

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Control

a sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle

Drug: Percutaneous injection
A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics

Active Comparator: Morphine

Drug: Morphine
Intrathecal injection of morphine 400mcg

Experimental: Morphine+bupivicaine

Drug: Morphine+Bupivacaine
Intrathecal injection of 5mg of 0.5% bupivacaine chloride

Outcome Measures

Primary Outcome Measures

  1. Time to first rescue analgesic [First 72 hours after surgery]

    Time to first rescue analgesic during the first 72 hours after surgery (hr) was our primary outcome.

Secondary Outcome Measures

  1. Pain score after surgery (visual analogue scale, VAS) [30 minutes, 1 hours upon arrival of the Postoperative anesthesia care unit(PACU), 5 hours post surgery, 1 day post-surgery]

    Visual analogue scale is a validated subjective measure for acute and chronic pain. Scores are measured on 10cm line where 0 represents no pain to 10cm representing the worst pain.

  2. Total fentanyl dose administered via intravenous patient-controlled analgesia (PCA) [First 48 hour post surgery]

    Further assessment of pain control was done by comparing total opioid dosage via PCA.

  3. Additional rescue analgesics given to the patient [until 3 days post-surgery.]

    Rescue analgesics were given only upon patients request. This was evaluated for further assessment of pain control.

  4. Sensory and motor block [30 minutes, 1 hours upon arrival of the Postoperative anesthesia care unit (PACU), 5 hours post surgery, 1 day post-surgery]

    Sensory and motor block was assessed for prolonged effects of intrathecal injection.

  5. Presence of complications (headache, nausea/vomiting, pruritus, respiratory depression, somnolence, low blood pressure, tingling, and shivering) [first 3 days post surgery]

    Common side effects to morphine or bupivacaine injections were assessed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age 19 years to no upper limit

  2. Patients receiving liver resection under general anesthesia (Including open surgery and laparoscopic surgery)

  3. American Society of Anesthesiologists (ASA) physical status 1,2

Exclusion Criteria:
  1. Patients presenting with coagulopathy prior to surgery

  2. Patients with neurological deficits

  3. Patients with spinal anomaly or disorders

  4. Patients with allergies to opioids or local anesthetics

  5. Patients with severe respiratory, cardiovascular, renal, or hepatic disorders

  6. Severe systemic infection or infections involving proposed intrathecal injection site

  7. Patients with severe psychological disorders severe that may interfere with pain evaluation

  8. Patients with chronic diseases that require opioids

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yonsei University Health System, Severance Hospital Seoul Korea, Republic of

Sponsors and Collaborators

  • Yonsei University

Investigators

  • Principal Investigator: Bon-Nye Koo, Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yonsei University
ClinicalTrials.gov Identifier:
NCT05208801
Other Study ID Numbers:
  • 4-2018-0838
First Posted:
Jan 26, 2022
Last Update Posted:
Jan 26, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 26, 2022